Arrowhead Research to Present at BIO-Europe 2012
Arrowhead Research to Present at BIO-Europe 2012
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NAS: ARWR) , a targeted therapeutics company, today announced that Dr. Chris Anzalone, President and Chief Executive Officer, will present a corporate overview at the 18th annual BIO-Europe international partnering conference on Tuesday, November 13th at 3:30 pm in Hamburg, Germany. BIO-Europe is the preeminent partnering conference serving the global biotechnology industry, with this year's event drawing 3,000 industry attendees from over 30 countries, representing close to 1,800 companies.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to ir@arrowres.com.
Arrowhead Research
Vince Anzalone, CFA
626-304-3400
or
The Trout Group
Lauren Glaser, 646-378-2972
ir@arrowres.com
KEYWORDS: United States Europe North America California Germany
INDUSTRY KEYWORDS:
The article Arrowhead Research to Present at BIO-Europe 2012 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
